| Segment Reporting [Table Text Block] |
The following table compares business segment revenues and business segment and Corporate operating income for the three months ended June 30, 2026 and 2025: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2026 | | (in millions) | | Healthcare | | AST | | Life Sciences | | Corporate | | Company | | Revenues | | $ | 1,048.3 | | | $ | 297.6 | | | $ | 146.7 | | | $ | — | | | $ | 1,492.7 | | | | | | | | | | | | | | Segment expenses | | | | | | | | | | | | Cost of revenues | | 589.1 | | | 140.1 | | | 66.0 | | | | | | | Selling, general, and administrative | | 173.9 | | | 14.0 | | | 16.4 | | | | | | | Research and development | | 25.1 | | | 0.6 | | | 2.5 | | | | | | | Total income from operations before adjustments | | $ | 260.2 | | | $ | 142.9 | | | $ | 61.8 | | | $ | (110.1) | | | $ | 354.8 | | | Less: Adjustments | | | | | | | | | | | Amortization of acquired intangible assets (1) | | | | | | | | | | 65.3 | | Acquisition and integration related charges (2) | | | | | | | | | | 1.5 | | Tax restructuring costs (3) | | | | | | | | | | 0.3 | | Amortization of inventory and property "step up" to fair value (1) | | | | | | | | | | 1.8 | | Total income from operations | | | | | | | | | | $ | 285.8 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, 2025 | | (in millions) | | Healthcare | | AST | | Life Sciences | | Corporate | | Company | | Revenues | | $ | 974.7 | | | $ | 281.2 | | | $ | 135.2 | | | $ | — | | | $ | 1,391.1 | | | | | | | | | | | | | | Segment expenses | | | | | | | | | | | | Cost of revenues | | 557.4 | | | 129.9 | | | 58.0 | | | | | | | Selling, general, and administrative | | 159.1 | | | 13.7 | | | 16.0 | | | | | | | Research and development | | 22.7 | | | 0.9 | | | 2.4 | | | | | | | Total income from operations before adjustments | | $ | 235.5 | | | $ | 136.7 | | | $ | 58.7 | | | $ | (114.0) | | | $ | 316.9 | | | Less: Adjustments | | | | | | | | | | | Amortization of acquired intangible assets (1) | | | | | | | | | | 67.1 | | Acquisition and integration related charges (2) | | | | | | | | | | 0.5 | | Tax restructuring costs (3) | | | | | | | | | | 0.2 | | Amortization of inventory and property "step up" to fair value (1) | | | | | | | | | | 1.4 | | Restructuring charges (4) | | | | | | | | | | 1.8 | | Total income from operations | | | | | | | | | | $ | 246.0 | | (1) For more information regarding our recent acquisitions, refer to Note 3 titled, "Business Acquisitions."(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring." | | | | | | | | | | | | | | | | (in millions) | | June 30, 2026 | | March 31, 2026 | | Assets | | | | | | Healthcare and Life Sciences | | $ | 7,141.9 | | | $ | 7,146.8 | | | AST | | 3,594.2 | | | 3,590.4 | | Total assets | | $ | 10,736.1 | | | $ | 10,737.2 | |
| | | | | | | | | | | | | | | | | Three Months Ended June 30, | | (in millions) | | 2026 | | 2025 | | Capital Expenditures | | | | | | Healthcare and Life Sciences | | $ | 42.2 | | | $ | 44.4 | | | AST | | 45.3 | | | 49.2 | | | Total Capital Expenditures | | $ | 87.5 | | | $ | 93.6 | | | Depreciation, Depletion, and Amortization | | | | | | Healthcare and Life Sciences | | $ | 81.0 | | | $ | 83.1 | | | AST | | 42.7 | | | 36.3 | | | Total Depreciation, Depletion, and Amortization | | $ | 123.8 | | | $ | 119.4 | |
| | | | | | | | | | | | | | | | (in millions) | | June 30, 2026 | | March 31, 2026 | | Property, Plant, and Equipment, Net | | | | | | Ireland | | $ | 87.6 | | | $ | 88.1 | | | United States | | 1,110.9 | | | 1,094.4 | | | Other locations | | 973.2 | | | 978.7 | | | Property, Plant, and Equipment, Net | | $ | 2,171.7 | | | $ | 2,161.2 | |
|
| Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Table Text Block] |
Additional information regarding our fiscal 2027 and fiscal 2026 revenue is disclosed in the following table: | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | (in millions) | | | | | | 2026 | | 2025 | | Healthcare: | | | | | | | | | | Capital equipment | | | | | | $ | 230.5 | | | $ | 227.3 | | | Consumables | | | | | | 391.9 | | | 358.9 | | Service | | | | | | 425.9 | | | 388.5 | | | Total Healthcare Revenues | | | | | | $ | 1,048.3 | | | $ | 974.7 | | | AST: | | | | | | | | | | Capital equipment | | | | | | $ | 1.4 | | | $ | 1.6 | | | Service | | | | | | 296.3 | | | 279.6 | | | Total AST Revenues | | | | | | $ | 297.6 | | | $ | 281.2 | | | Life Sciences: | | | | | | | | | | Capital equipment | | | | | | $ | 31.3 | | | $ | 26.6 | | | Consumables | | | | | | 81.5 | | | 75.3 | | | Service | | | | | | 34.0 | | | 33.3 | | | Total Life Sciences Revenues | | | | | | $ | 146.7 | | | $ | 135.2 | | | Total Revenues | | | | | | $ | 1,492.7 | | | $ | 1,391.1 | |
|